Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

RYBREVANT® (amivantamab-vmjw)

Medical Information

+ Save link

RYBREVANT - CHRYSALIS Study

Last Updated: 02/15/2025

Summary

A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:

RYBREVANT^® (amivantamab-vmjw) – CHRYSALIS Study
- Minimum requirement to access interactive content: Adobe Acrobat Reader
An overview of the CHRYSALIS Cohort D study design and results is available in video format: VIDEO LINK.
The executive summary infographic of the iPDF content is provided below.

A screenshot of a computer

AI-generated content may be incorrect.

PRODUCT LABELING

RYBREVANT (amivantamab-vmjw) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf.
LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf.